Biosimilar nomenclature: Deadline August 2 for comments on FDA’s OMB information request

Admin — Thu, 02 Jun 2016 17:32:22 +0000

Meaningful suffix may be in for U.S. biologics, biosimilars

FDA Pushes Back Comment Period for Biosimilar Labeling

Just released: new deadline August?2 for information collection request it submitted to the White House Office of Management and Budget (OMB)

Additional Reading

FDA approves Inflectra, a biosimilar to Remicade

A Rocky Start for Biosimilar Inflectra?

FDA Approves INFLECTRA? (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States

FDA Information on Biosimilars

" data-image-caption="" data-medium-file="https://i0.wp.com/3sixtypharma.com/wp-content/uploads/2018/01/Certifications.png?fit=300%2C38&ssl=1" data-large-file="https://i0.wp.com/3sixtypharma.com/wp-content/uploads/2018/01/Certifications.png?fit=640%2C81&ssl=1" class="aligncenter size-full wp-image-1869" src="https://i0.wp.com/3sixtypharma.com/wp-content/uploads/2018/01/Certifications.png?resize=640%2C81&ssl=1" alt="" width="640" height="81" srcset="https://i0.wp.com/3sixtypharma.com/wp-content/uploads/2018/01/Certifications.png?w=664&ssl=1 664w, https://i0.wp.com/3sixtypharma.com/wp-content/uploads/2018/01/Certifications.png?resize=300%2C38&ssl=1 300w" sizes="(max-width: 640px) 100vw, 640px" data-recalc-dims="1" />

White House OMB – 3Sixty Pharma Solutions LLC

Biosimilar nomenclature: Deadline August 2 for comments on FDA’s OMB information request

Meaningful suffix may be in for U.S. biologics, biosimilars

FDA Pushes Back Comment Period for Biosimilar Labeling